Perrigo Predicts Cough/Cold Sales Drop Due To Pseudoephedrine BTC Move
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's cough/cold sales will likely be hurt in fiscal 2006 as retailers restrict pseudoephedrine products to behind-the-counter sale, according to the firm
You may also be interested in...
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date